https://www.selleckchem.com/products/gsk343.html
Novel therapies, including cell and gene therapies, can radically improve outcomes among patients with rare disorders, especially if provided early. Newborn screening (NBS) could support early access to novel therapies, but the speed of new therapy development is a disruptive event for which the public health NBS system and state newborn screening programs are unprepared. To identify and evaluate possible solutions for modernizing NBS. In this survey study, NBS experts representing clinical research, federal or state advisory boards, pat
Like
Comment
Share
